Gilead Sciences, Inc. $GILD Shares Bought by Mn Services Vermogensbeheer B.V.

Mn Services Vermogensbeheer B.V. raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 368,039 shares of the biopharmaceutical company’s stock after purchasing an additional 6,400 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in Gilead Sciences were worth $54,856,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in GILD. BlackRock Inc. acquired a new position in shares of Gilead Sciences in the 2nd quarter valued at about $15,393,785,000. State Street Corp boosted its stake in shares of Gilead Sciences by 2.3% in the second quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock worth $7,734,099,000 after buying an additional 1,357,967 shares during the last quarter. Invesco Ltd. grew its holdings in Gilead Sciences by 2.9% during the fourth quarter. Invesco Ltd. now owns 15,584,341 shares of the biopharmaceutical company’s stock worth $1,912,822,000 after acquiring an additional 444,660 shares during the period. Amundi grew its holdings in Gilead Sciences by 10.7% during the first quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock worth $1,468,836,000 after acquiring an additional 1,018,976 shares during the period. Finally, Legal & General Group Plc purchased a new position in Gilead Sciences during the second quarter valued at approximately $1,316,606,000. 83.67% of the stock is owned by institutional investors and hedge funds.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Analyst support remains strong. JPMorgan raised its price target to $170 while maintaining an overweight rating, and Truist increased its target to $158 with a buy rating. Cantor Fitzgerald also reaffirmed its overweight rating with a $155 target. These targets imply further upside and may be supporting investor sentiment.
• Positive Sentiment: Morgan Stanley issued a buy rating. The new endorsement adds another positive institutional view, although Morgan Stanley separately trimmed its price target from $165 to $163 while retaining an overweight rating. Morgan Stanley Gives a Buy Rating to Gilead Sciences
• Positive Sentiment: Recent operating results provide a favorable backdrop. Gilead’s latest quarterly revenue increased 10.6% year over year to $7.80 billion and exceeded estimates, while reported EPS also surpassed consensus expectations. A review of second-quarter results highlights the company’s performance relative to other therapeutics companies. Therapeutics Stocks Q2 Highlights: Gilead Sciences
• Positive Sentiment: Gilead expanded its technology infrastructure. A five-year DevOps agreement with Cognizant is intended to improve processes by combining Cognizant’s technical capabilities with life-sciences expertise. The deal is strategically supportive, though its direct near-term financial impact is unclear. Gilead Sciences signs five-year DevOps agreement with Cognizant
• Neutral Sentiment: Gilead’s collaboration with Nurix Therapeutics was extended by two years for an oncology research program. The extension signals ongoing progress in protein-degradation research and preserves potential milestone payments and royalties, but the program remains uncertain and is not an immediate revenue driver. Extending the Gilead E3 Ligase Collaboration
• Negative Sentiment: RBC remains cautious. Although RBC raised its price target to $126, it maintained a sector perform rating. The target remains below the current trading level, highlighting valuation concerns and providing a counterweight to the more bullish analyst calls. RBC raises Gilead Sciences price target

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on GILD. Leerink Partners downgraded Gilead Sciences from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $146.00 to $127.00 in a report on Tuesday, July 21st. Wall Street Zen raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, September 19th. Barclays cut their target price on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a report on Wednesday, July 29th. Needham & Company LLC reiterated a “buy” rating and issued a $170.00 target price on shares of Gilead Sciences in a research note on Wednesday, August 5th. Finally, JPMorgan Chase & Co. increased their price target on shares of Gilead Sciences from $160.00 to $170.00 and gave the stock an “overweight” rating in a report on Wednesday. Twenty-three analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $159.26.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $147.10 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The stock has a market capitalization of $182.40 billion, a PE ratio of -55.09 and a beta of 0.31. Gilead Sciences, Inc. has a fifty-two week low of $114.02 and a fifty-two week high of $157.29. The company has a fifty day moving average of $144.71 and a two-hundred day moving average of $136.62.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. During the same quarter in the previous year, the company earned $2.01 earnings per share. The company’s quarterly revenue was up 10.6% on a year-over-year basis. As a group, research analysts forecast that Gilead Sciences, Inc. will post -0.48 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th were paid a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.2%. The ex-dividend date was Tuesday, September 15th. Gilead Sciences’s payout ratio is -122.85%.

Insider Buying and Selling at Gilead Sciences

In related news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the completion of the sale, the insider directly owned 118,234 shares in the company, valued at approximately $16,273,727.76. The trade was a 19.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 15,000 shares of the stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $148.64, for a total value of $2,229,600.00. Following the completion of the transaction, the chief executive officer directly owned 577,133 shares of the company’s stock, valued at approximately $85,785,049.12. This represents a 2.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 105,000 shares of company stock valued at $14,940,540. 0.30% of the stock is owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc (NASDAQ: GILD) is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. Its research and commercial activities focus primarily on virology, including HIV, hepatitis B and hepatitis C, as well as oncology, inflammation and other areas of significant unmet medical need.

Gilead’s portfolio includes HIV treatments such as Biktarvy, Descovy, Genvoya and Sunlenca; hepatitis therapies including Epclusa, Harvoni and Vemlidy; and Veklury (remdesivir), an antiviral used to treat COVID-19 in certain patients.